

SHCP APC Summary

Date: September 2023

Link to the full September SHCP APC minutes are available [HERE](#)

SHCP APC item	Summary of decision
<p>Adopt the NHSE commissioning recommendations for blood glucose and ketone meters, test strips and lancets recommendations for blood glucose and ketone meters, test strips and lancets</p>	<p>Approved The NHSE recommended test strips and lancets that are on the Drug Tariff to be added to the Sussex Partner formulary with a GREEN (can be prescribed in any care setting) formulary coding. To remove those meters, test strips and lancets from the formulary that are outside of NHSE recommendations (except for Fastclix). To include on the formulary “Where a patient is on an insulin pump that requires a specific meter and test strips not on NHSE recommended list, these should continue, and the reason documented”. The OptimiseRx platform will be updated with additional messages to support prescribing the most cost-effective test strips and lancets.</p>
<p>Bibecfo Metered Dose Inhaler (MDI) (100/6 MDI and 200/6 MDI) formulary extension application</p>	<p>Approved with a GREEN (can be prescribed in any care setting) formulary coding as first line for new patients only.</p>
<p>Tostran gel and Testogel sachet for low libido in postmenopausal women new medicine application</p>	<p>Approved with a PURPLE (Specialist recommended) formulary coding. All other indications that are not already listed on the Sussex Partner Formulary to be coded RED. The committee confirmed that if a patient has previously been initiated on testosterone treatment and has documented benefit they would continue with treatment and be monitored as a default position if already started on treatment.</p>
<p>Rimegepant 75 mg oral lyophilisate ▼ change in formulary coding application (NICE TA906 Rimegepant for preventing migraine)</p>	<p>Approved with a RED formulary coding Rimegepant is an oral medicine that can be prescribed for the prophylaxis of migraine.</p>
<p>Wound care chapter formulary review</p>	<p>Approved The wound care formulary chapter review brought together a community and primary care wound care pathway across Sussex supporting the national wound care programme. This updated formulary includes community and primary care but does not include secondary care due to the specification for the products differ due to the</p>

	different types of wounds and duration of dressings being left in place.
Not recommended medicines to be included within the 'Not Recommended' list on the Sussex Partner Formulary	Approved To add previously agreed 'not approved' medicines to the 'Not Recommended' list. The medicines include: Trixeo® pMDI (July 2022 APC) Ustekinumab - escalation of dosing frequency to every 4-6 weeks. (Sept 2022 APC) Dexamfetamine 5mg/5ml sugar free oral solution (May 2023 APC) Methylphenidate - Delmosart® prolonged release tablets, Ritalin® XL capsules all strengths. (May 2023 APC) Luforbec® MDI (July 2023 APC)
SHCP APC item	Virtually approved
NICE TA902 – dapagliflozin Following an amendment made by NICE which now highlights that providers are NHS hospital trusts and primary care.	Approved with a PURPLE (Specialist initiation without Shared Care Protocol) formulary coding for use as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
NICE Technology Appraisals	
NICE TA908 Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy.	Approved RED formulary coding
NICE TA909 Lorlatinib for untreated ALK-positive advanced non-small cell lung cancer	Not recommended
NICE TA910 Semaglutide for managing overweight and obesity in young people aged 12 to 17 years	Terminated appraisal
NICE TA911 Selpercatinib for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults.	Approved RED formulary coding
NICE TA912 Cimaglucosidase alfa with miglustat for treating late-onset Pompe disease in adults.	Approved RED formulary coding
HST27 Afamelanotide for treating erythropoietic protoporphyria	Not recommended

NICE Guidelines	
CG189	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG122	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG83	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG233	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG12	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG126	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG158	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
Discontinuations	
March 2023	Ketovite tablets
May 2023	Nutrison MCT 500ml
September 2023	Nutrison MCT 1000ml